The old rule in Silicon Valley, don't invest in competing startups, is losing its grip, and Benchmark's acknowledgment of that shift is more than a confession; it's a signal that the venture playbook is being rewritten. For founders and operators who have felt the friction of an investor backing a direct competitor, this change cuts both ways. It opens the door for more capital to flow into dense markets, but it also demands a sharper eye for alignment.
Benchmark, a firm that has long personified the Valley's traditional restraint, now says the rule against backing rivals is "getting harder to keep." That's not a casual observation. It reflects a structural reality: the most promising startups often cluster in the same emerging categories, and venture firms that rigidly avoid overlap risk sitting out the next wave. The practical consequence for our readers is straightforward. If you're raising capital, expect more investors to have portfolio companies that share your market. The question is no longer whether they do, but whether their support remains transparent and undistracted. This trend also echoes dynamics we've seen play out in hardware and biotech. Consider how Intero Biosystems wins $100K grand prize at Disrupt 2026 Startup Battlefield pulled ahead of nearly 200 other startups, competition for attention and capital is intensifying, and investors are recalibrating their strategies to back multiple bets in a space rather than picking a single winner early.
At the same time, the breakdown of this norm puts more pressure on due diligence. When an investor can fund two companies in the same vertical, the potential for information flow or divided loyalty grows. Founders need to ask harder questions about governance, information barriers, and how the investor handles conflict. This isn't a theoretical worry. In the AI tools space, for example, the line between complementary and competing products is often blurry, as What to Know Before Using Abacus AI illustrates, users and investors alike must weigh reliability and real-world performance against marketing claims. The same scrutiny should apply to venture relationships.
The takeaway here is direct: don't assume an investor's existing portfolio is a safe harbor. Ask for a list of current bets in your category. Ask how they handle confidential information when two portfolio companies compete. And watch whether their actions align with their stated philosophy. Benchmark's admission is honest, but it also normalizes a practice that could erode trust if handled carelessly. The specific detail to monitor is how top-tier firms update their standard term sheets and side letters to address this new reality. If they don't, founders should.